ReviewBiomarker research2025
Arginine methylation in cancer: mechanisms and therapeutic implications.
Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications.Journal of gastroenterology and hepatology · 2026Review
- Identification of E3 Ubiquitin Ligases Associated with Survival in Soft Tissue Sarcomas.International journal of molecular sciences · 2026Article
- Protein arginine methyltransferases coordinate mitochondrial stress adaptation and neuromuscular function.Experimental & molecular medicine · 2026Review
- PRMT5 as a Key Driver of Stemness and Metastatic Potential in Triple-Negative Breast Cancer.Biomolecules · 2026Review
- Protein Arginine Methyltransferases in γ-Globin Regulation and Sickle Cell Disease: Emerging Connections to Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- TRIM47: molecular characteristics, disease-related mechanisms, and clinical translational value.Frontiers in immunology · 2026Review
- Multi-Omics and Clinical Data Analyses of Protein Arginine Methyltransferases in Pan-Cancer and Colorectal Cancer.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Arginine methylation is a critical post-translational modification that modulates protein stability, enzymatic activity, and subcellular localization, thereby shaping cell fate decisions and maintaining cellular homeostasis. As the principal enzymes catalyzing this modification, protein arginine methyltransferases (PRMTs) participate in key biological processes, including transcriptional and post-transcriptional regulation as well as signal transduction. Dysregulated PRMT activity has been increasingly linked to tumor initiation, progression, and therapeutic resistance. This review summarizes PRMT classification, structural and functional characteristics, and upstream regulatory mechanisms, offering a framework for understanding their diverse roles in cancer biology and therapeutic relevance. We further discuss the mechanistic contributions of PRMTs to multiple cancer hallmarks and highlight recent advances in the development of PRMT inhibitors. Finally, we examine current strategies for clinical translation, with particular emphasis on combination approaches involving chemotherapy, targeted therapy, and immunotherapy, thereby offering a foundation for advancing PRMT-targeted precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.